Related Experiment Video

Updated: May 27, 2026

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)
10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

M Javle1, N J Curtin

  • 1Associate Professor, UT-MD Anderson Cancer Center, Houston, TX, USA.

Therapeutic Advances in Medical Oncology
|November 16, 2011
PubMed

Insights

Poly (ADP-ribose) polymerase inhibitors (PARPi) are revolutionizing cancer therapy by targeting DNA repair. These drugs show promise for BRCA-mutant cancers and beyond, but resistance and inhibitor differences require further study.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a significant advancement in cancer therapeutics.
  • PARP enzymes are crucial for repairing single-strand DNA breaks, and their inhibition can lead to lethal double-strand breaks in cancer cells with deficient homologous recombination repair.

Purpose of the Study:

  • To review the current literature on poly (ADP-ribose) polymerase inhibitors (PARPi) in cancer therapy.
  • To highlight the therapeutic potential of PARPi, particularly in BRCA-mutant cancers and other DNA repair-deficient tumors.
  • To discuss the challenges and future directions in PARPi development, including resistance mechanisms and the need to differentiate between various inhibitors.

Main Methods:

  • Literature review of studies on poly (ADP-ribose) polymerase inhibitors (PARPi).
  • Analysis of PARPi mechanisms of action and synergistic effects with other cancer treatments.
  • Examination of clinical trial outcomes and resistance patterns associated with PARPi therapy.

Main Results:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective in cancers with defects in DNA repair pathways, especially BRCA mutations.
  • Synergistic antitumor effects are observed when PARPi are combined with chemotherapy (e.g., cisplatin, temozolomide) and radiation.
  • Clinical development is ongoing, but challenges such as acquired resistance and the need to distinguish between different PARPi agents are emerging.

Conclusions:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) are a validated therapeutic strategy for specific cancer types.
  • The application of PARPi may extend to a broader range of cancers with DNA repair deficiencies.
  • Understanding the nuances between different PARPi and overcoming resistance are critical for maximizing their clinical utility.
Keywords:
BRCA2 geneDNA repair-deficiency disorderspoly (ADP-ribose) polymerases

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...